candesartan has been researched along with Kidney Diseases in 39 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors." | 9.10 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. ( Granger, CB; Held, P; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Yusuf, S, 2003) |
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 7.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 7.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1." | 6.43 | Candesartan in heart failure. ( Chonlahan, JS; Germany, RE; Ripley, TL, 2006) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 5.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| "Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors." | 5.10 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. ( Granger, CB; Held, P; McMurray, JJ; Michelson, EL; Olofsson, B; Ostergren, J; Pfeffer, MA; Swedberg, K; Yusuf, S, 2003) |
| "In a private consulting practice setting, the addition of 8 mg of Candesartan in normotensive patients with chronic renal disease and proteinuria receiving an ACEI reduced proteinuria and blood pressure." | 5.10 | Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. ( Fairley, K; Kincaid-Smith, P; Packham, D, 2002) |
| "Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients." | 4.95 | Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. ( Feng, Y; Huang, R; Li, X; Melgiri, ND; Qin, X; Sun, Y; Wang, Y, 2017) |
| " show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation." | 4.84 | Candesartan and renal protection: more than blocking angiotensin type 1 receptor? ( Macconi, D; Remuzzi, G, 2008) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 3.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| "To examine the additive protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone (Pio) and the angiotensin II receptor blocker candesartan (Cand) in a murine model of renal fibrosis: mice with unilateral ureteral obstruction (UUO)." | 3.76 | Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. ( Higashi, K; Hyodo, T; Kumagai, H; Kushiyama, T; Miura, S; Oda, T; Sakurai, Y; Suzuki, S; Yamada, M, 2010) |
| "The Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity (CHARM) program consisted of three component trials that enrolled patients with symptomatic CHF, based on use of ACE inhibitors and reduced (< or =40%) or preserved LVEF (>40%)." | 3.73 | Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. ( Cornel, JH; de Zeeuw, D; Granger, CB; Hillege, HL; McMurray, JJ; Michelson, EL; Nitsch, D; Ostergren, J; Pfeffer, MA; Pocock, S; Swedberg, K; van Veldhuisen, DJ; Yusuf, S, 2006) |
| " In addition to treatment with prednisolone, they were administered anticoagulants(warfarin, or aspirin, or heparin) for APSN and an angiotensin II receptor blocker, candesartan, for the hypertension." | 3.71 | [Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis]. ( Kawakami, K; Komiya, T; Negoro, N; Okada, S; Okamura, M; Okazaki, M; Sumi, T; Tsukamoto, J; Yoshikawa, J, 2002) |
| " The authors randomly assigned 269 patients who had persistent proteinuria (> or =1 g/d) despite 7 wk of treatment with the highest approved dosage of candesartan (16 mg/d) to 16, 64, or 128 mg/d candesartan for 30 wk." | 2.74 | Supramaximal dose of candesartan in proteinuric renal disease. ( Burgess, E; Chiu, A; Muirhead, N; Pichette, V; Rene de Cotret, P; Tobe, S, 2009) |
| "Candesartan is an angiotensin II subtype 1 (AT1) receptor antagonist that is administered orally as candesartan cilexetil which is converted in the active compound." | 2.69 | Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. ( Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999) |
| "Candesartan cilexetil is a nonpeptide selective blocker of the angiotensin II receptor sub-type 1." | 2.43 | Candesartan in heart failure. ( Chonlahan, JS; Germany, RE; Ripley, TL, 2006) |
| " It compared the antihypertensive effect between increasing ARB dosage and the addition of controlled-release nifedipine." | 2.43 | [NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection]. ( Hasebe, N, 2006) |
| " No relevant pharmacokinetic drug-food or drug-drug interactions are known." | 2.41 | Clinical pharmacokinetics of candesartan. ( Gleiter, CH; Mörike, KE, 2002) |
| "Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 1.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 25 (64.10) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Yasuno, S | 1 |
| Oba, K | 1 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 1 |
| Ueshima, K | 1 |
| Ahmed, HI | 1 |
| Mohamed, EA | 1 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Wang, Y | 2 |
| Qin, X | 1 |
| Melgiri, ND | 1 |
| Sun, Y | 1 |
| Li, X | 1 |
| Huang, J | 1 |
| Liu, X | 1 |
| Niu, Y | 1 |
| Zhao, L | 1 |
| Yu, Y | 1 |
| Zhou, L | 1 |
| Lu, L | 1 |
| Yu, C | 1 |
| Chen, S | 1 |
| Ge, Y | 1 |
| Si, J | 1 |
| Rifai, A | 1 |
| Dworkin, LD | 1 |
| Gong, R | 1 |
| Macconi, D | 1 |
| Remuzzi, G | 2 |
| Burgess, E | 1 |
| Muirhead, N | 1 |
| Rene de Cotret, P | 1 |
| Chiu, A | 1 |
| Pichette, V | 1 |
| Tobe, S | 1 |
| de Zeeuw, D | 3 |
| Lambers-Heerspink, H | 1 |
| Saruta, T | 2 |
| Hayashi, K | 3 |
| Ogihara, T | 1 |
| Nakao, K | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Chung, S | 1 |
| Park, CW | 1 |
| Shin, SJ | 1 |
| Lim, JH | 1 |
| Chung, HW | 1 |
| Youn, DY | 1 |
| Kim, HW | 1 |
| Kim, BS | 1 |
| Lee, JH | 1 |
| Kim, GH | 1 |
| Chang, YS | 1 |
| Frimodt-Møller, M | 1 |
| Høj Nielsen, A | 1 |
| Strandgaard, S | 1 |
| Kamper, AL | 1 |
| Sasamura, H | 2 |
| Ishiguro, K | 1 |
| Sakamaki, Y | 1 |
| Azegami, T | 2 |
| Itoh, H | 2 |
| Suzuki, H | 3 |
| Takenaka, T | 2 |
| Higashi, K | 1 |
| Oda, T | 1 |
| Kushiyama, T | 1 |
| Hyodo, T | 1 |
| Yamada, M | 1 |
| Suzuki, S | 1 |
| Sakurai, Y | 1 |
| Miura, S | 1 |
| Kumagai, H | 2 |
| Ecelbarger, CM | 1 |
| Rash, A | 1 |
| Sinha, RK | 1 |
| Tiwari, S | 1 |
| Schmaderer, C | 1 |
| Xing, CJ | 1 |
| Anderson, G | 1 |
| Hermans, R | 1 |
| Lutz, J | 1 |
| Heemann, U | 1 |
| Baumann, M | 1 |
| Chen, X | 1 |
| Mori, T | 1 |
| Guo, Q | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Zhu, W | 1 |
| Jiang, Y | 1 |
| Endo, S | 1 |
| Nakayama, K | 1 |
| Ogawa, S | 1 |
| Nakayama, M | 1 |
| Miyata, T | 1 |
| Ito, S | 1 |
| Padi, SS | 1 |
| Chopra, K | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| Goicoechea, MA | 1 |
| González, C | 1 |
| de Vinuesa, SG | 1 |
| Gómez, F | 1 |
| Bernis, C | 1 |
| Espinosa, M | 1 |
| Ahijado, F | 1 |
| Gómez, J | 1 |
| Escalada, P | 1 |
| Komiya, T | 1 |
| Okamura, M | 1 |
| Kawakami, K | 1 |
| Okazaki, M | 1 |
| Tsukamoto, J | 1 |
| Okada, S | 1 |
| Sumi, T | 1 |
| Negoro, N | 1 |
| Yoshikawa, J | 1 |
| Terra, SG | 1 |
| Granger, CB | 2 |
| McMurray, JJ | 2 |
| Yusuf, S | 2 |
| Held, P | 1 |
| Michelson, EL | 2 |
| Olofsson, B | 1 |
| Ostergren, J | 2 |
| Pfeffer, MA | 2 |
| Swedberg, K | 2 |
| de Borst, MH | 1 |
| Navis, G | 1 |
| de Boer, RA | 1 |
| Huitema, S | 1 |
| Vis, LM | 1 |
| van Gilst, WH | 1 |
| van Goor, H | 1 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Debelle, FD | 1 |
| Nortier, JL | 1 |
| Husson, CP | 1 |
| De Prez, EG | 1 |
| Vienne, AR | 1 |
| Rombaut, K | 1 |
| Salmon, IJ | 1 |
| Deschodt-Lanckman, MM | 1 |
| Vanherweghem, JL | 1 |
| Ogata, C | 1 |
| Kamide, K | 1 |
| Suzuki, Y | 1 |
| Sasaki, O | 1 |
| Kubota, Y | 1 |
| Sato, H | 1 |
| Takiuchi, S | 1 |
| Horio, T | 1 |
| Inenaga, T | 1 |
| Kawano, Y | 1 |
| Hillege, HL | 1 |
| Nitsch, D | 1 |
| Cornel, JH | 1 |
| Pocock, S | 1 |
| van Veldhuisen, DJ | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Tomasoni, S | 1 |
| Campana, M | 1 |
| Corna, D | 1 |
| Zanchi, C | 1 |
| Gagliardini, E | 1 |
| Garofano, E | 1 |
| Rottoli, D | 1 |
| Ito, T | 1 |
| Kanno, Y | 2 |
| Chandar, J | 1 |
| Abitbol, C | 1 |
| Montané, B | 1 |
| Zilleruelo, G | 1 |
| Nakamura, T | 1 |
| Ripley, TL | 1 |
| Chonlahan, JS | 1 |
| Germany, RE | 1 |
| Hasebe, N | 1 |
| Buter, H | 1 |
| Navis, GY | 1 |
| Woittiez, AJ | 1 |
| de Jong, PE | 1 |
| Ramahi, TM | 1 |
| Gleiter, CH | 1 |
| Mörike, KE | 1 |
| Thurston, H | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, K | 1 |
| Packham, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S[NCT00242346] | Phase 3 | 270 participants | Interventional | 2003-04-30 | Completed | ||
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients With Preserved Ejection Fraction[NCT03111017] | 12 participants (Actual) | Interventional | 2017-04-17 | Completed | |||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure[NCT02133105] | Phase 3 | 33 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
10 reviews available for candesartan and Kidney Diseases
| Article | Year |
|---|---|
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2017 |
Candesartan and renal protection: more than blocking angiotensin type 1 receptor?
Topics: Angiotensin II Type 1 Receptor Blockers; Antioxidants; Benzimidazoles; Biphenyl Compounds; Humans; I | 2008 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimida | 2010 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[E-COST].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2006 |
Candesartan in heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Death, Sudden; Heart Fa | 2006 |
[NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Doubl | 2006 |
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Clinical pharmacokinetics of candesartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biological Availability; | 2002 |
Dual angiotensin II blockade: a promise of enhanced renal protection?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
8 trials available for candesartan and Kidney Diseases
| Article | Year |
|---|---|
Supramaximal dose of candesartan in proteinuric renal disease.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetic N | 2009 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2010 |
Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2003 |
Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bi | 1999 |
Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2002 |
21 other studies available for candesartan and Kidney Diseases
| Article | Year |
|---|---|
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Candesartan and epigallocatechin-3-gallate ameliorate gentamicin-induced renal damage in rats through p38-MAPK and NF-κB pathways.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caspase 3; Catechin; Drug Therapy, Combination; Gene Ex | 2019 |
β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; beta-Arrestin 1; b | 2017 |
Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2008 |
Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; | 2010 |
Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Be | 2010 |
Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biomarkers; Biphenyl | 2010 |
The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cytokines; Die | 2010 |
AGE formation blockade with aminoguanidine does not ameliorate chronic allograft nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiotonic Ag | 2011 |
Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan.
Topics: Acetyl-CoA C-Acetyltransferase; Angiotensin Receptor Antagonists; Animals; Apolipoproteins E; Athero | 2012 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |
Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2002 |
[Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis].
Topics: Adult; Angiotensin Receptor Antagonists; Anticoagulants; Antigen-Antibody Complex; Antihypertensive | 2002 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats.
Topics: Actins; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified | 2003 |
The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aristolo | 2004 |
Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Hemodynamics; H | 2005 |
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Fai | 2006 |
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Fai | 2006 |
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Fai | 2006 |
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Fai | 2006 |
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Gene Expression Regul | 2006 |
Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angio | 2007 |